Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
About the Author
Discover more from InfoVera USA
Subscribe to get the latest posts sent to your email.
US News, Trends & Trusted Information
